Results 21 to 30 of about 2,523,178 (262)
Haematologica, 2018 Targeted therapies against FLT3-mutated acute myeloid leukemias have shown limited clinical efficacy primarily because of the acquisition of secondary mutations in FLT3 and persistent activation of downstream pro-survival pathways such as MEK/ERK, PI3K ...
Weiguo Zhang +7 more
doaj +1 more source
Frontiers in Immunology, 2022 Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with recurrent/refractory acute myeloid leukemia (AML).
Hong Mu-Mosley +7 more
doaj +1 more source
Superoxide Dismutase and Vitamin E Levels in Serum as Indicators in Patients with Acute and Chronic Leukemia [PDF]
Journal of Applied Sciences and Nanotechnology, 2022 Oxidative stress has been linked to the development of a variety of malignancies, including leukemia. Furthermore, the incidence of leukemia increases with age due to an increase in the number of free radicals reacting with age and a lower ability of the
Reem Al-Qaisi +2 more
doaj +1 more source
Targeting the MLL complex in acute leukemia [PDF]
, 2014 Chromosomal rearrangements leading mostly to fusion oncoproteins of the Mixed Lineage Leukemia (MLL) gene occur in about 10% of all patients with acute leukemia and are often associated with poor clinical outcome, emphasizing the need for new treatment ...
Méreau, Hélène
core +1 more source
Cells, 2023 Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Common causes include gram-negative and gram-positive bacteria as well as fungi.
Øystein Bruserud +4 more
doaj +1 more source
Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides [PDF]
, 2012 In acute promyelocytic leukemia (APL), hematopoietic differentiation is blocked and immature blasts accumulate in the bone marrow and blood. APL is associated with chromosomal aberrations, including t(15;17) and t(11;17).
Sabine Beez (123610) +8 more
core +1 more source
Hemato, 2021 About 10% of newly diagnosed and 20–30% of therapy-related acute myeloid leukemia (AML) harbors a TP53 mutation (mTP53-AML). Unfortunately, this biological subset predicts one of the worst prognoses among patients with AML, specifically a median overall ...
Rory M. Shallis +3 more
doaj +1 more source
Oncology Reviews, 2011 Tyrosine kinase inhibitors (TKIs) are the mainstay for treatment of chronic myelogenous leukemia (CML). Imatinib was the first TKI approved for use in CML, but resistance to this therapy has emerged as a significant issue, and second-line options are ...
Michael G. Martin +2 more
doaj +1 more source
Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang
Cancer Biology & Medicine, 2016 Acute myeloid leukemia (AML) is characterized by the accumulation of circulating immature blasts that exhibit uncontrolled growth, lack the ability to undergo normal differentiation, and have decreased sensitivity to apoptosis.
Hong-Sheng Zhou +2 more
doaj +1 more source
, 2018 Deferasirox (DFX), in addition to its iron-chelation property, has marked anti-proliferative effects on cancer cells. However, the activity and mechanism by which DFX inhibits acute myeloid leukemia (AML) cells remain to be elucidated.
Huang, Yu-Ting +8 more
core +1 more source